Aptose Biosciences INC

Aptose Biosciences announced positive safety, response, and MRD data from its TUSCANY Phase 1/2 trial of tuspetinib triplet therapy in newly diagnosed AML patients at the 2026 EHA Congress.

Aptose Biosciences reports a delay in the closing of its acquisition by Hanmi Pharmaceutical due to pending Korean regulatory approvals, now targeting a June completion.

Aptose Biosciences reports Q1 2026 financial results while awaiting regulatory approval for its acquisition by Hanmi Pharmaceutical.

Aptose Biosciences announced a delay in the closing of its acquisition by Hanmi Pharmaceutical due to pending Korean regulatory approvals, now targeting May for completion.

Aptose Biosciences shareholders approved its acquisition by Hanmi Pharmaceutical, with the company also reporting its year-end 2025 financial results and positive clinical data for its AML therapy.

Aptose Biosciences shareholders overwhelmingly approved the plan of arrangement for acquisition by Hanmi Pharmaceutical and a corporate continuance to Alberta.

Aptose Biosciences reports Q1 2026 financial results while navigating a pending acquisition by Hanmi Pharmaceutical.

Aptose Biosciences reports promising clinical data for its lead drug tuspetinib in AML, but faces significant financial challenges including a going concern warning and Nasdaq delisting.

Aptose Biosciences reports promising clinical data for its lead cancer drug, tuspetinib, but faces significant financial challenges including a Nasdaq delisting and substantial doubt about its ability to continue as a going concern.

Aptose Biosciences reports Q1 2025 results with ongoing concerns about its ability to continue as a going concern, despite clinical advancements with its lead drug candidate, tuspetinib.

Aptose Biosciences reported a net loss of $6.95 million for Q3 2024, compared to $11.45 million in Q3 2023, and faces ongoing challenges regarding Nasdaq listing requirements.

Aptose Biosciences reported its Q2 2024 financial results, highlighting ongoing clinical trial progress for tuspetinib while facing significant financial challenges and going concern doubts.

Aptose Biosciences is set to be acquired by Hanmi Pharmaceutical for C$2.41 per share, providing a definitive path forward for the company despite ongoing financial challenges and promising clinical results for its lead oncology asset, tuspetinib.

Aptose Biosciences Inc. files its 2024 10-K, highlighting clinical advancements in tuspetinib and luxeptinib programs while addressing financial challenges and Nasdaq compliance.

Aptose Biosciences Inc. filed an amendment to its annual report on Form 10-K to include information previously omitted regarding directors, executive officers, and corporate governance.

Aptose Biosciences Inc. released its annual 10-K filing, detailing financial results and progress in clinical trials for its lead drug candidates, tuspetinib and luxeptinib.

Bernd R. Seizinger, former director of Aptose Biosciences Inc., reported transactions involving common shares and stock options on June 30, 2026, related to a business arrangement agreement.

Warren Whitehead reports changes in beneficial ownership of Aptose Biosciences Inc. common shares and stock options, reflecting a business arrangement agreement.

Former Aptose Biosciences director Mark D. Vincent has disposed of common shares and exercised stock options as part of a business arrangement agreement leading to the company's acquisition.

William G. Rice, CEO of Aptose Biosciences, reported changes in his beneficial ownership of company securities, including the disposition of common shares and various derivative securities.

Erich Platzer, former director of Aptose Biosciences Inc., has reported transactions involving common shares and stock options.

Fletcher Payne, former SVP and CFO of Aptose Biosciences, reported the disposition of common shares and stock options following the company's acquisition by Hammi Pharmaceuticals.

Aptose Biosciences Inc. shareholders will vote on a C$2.41 per share cash acquisition by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., following a board recommendation.

Aptose Biosciences selects Ernst & Young as its new independent auditor and calls a reconvened meeting of shareholders for August 22, 2025.

Aptose Biosciences focuses on advancing its tuspetinib-based triplet therapy for AML and seeks shareholder approval for a reverse stock split and stock incentive plan amendment at the upcoming annual meeting.

Aptose Biosciences Inc. will hold a special meeting on January 27, 2025, for shareholders of record as of December 24, 2024.

Aptose Biosciences is asking shareholders to approve a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and enhance the marketability of its shares.

Aptose Biosciences is holding a special meeting on August 15, 2024, to seek shareholder approval for the issuance of common shares underlying certain warrants, as required by Nasdaq listing rules.

Aptose Biosciences has filed a registration statement for the potential resale of up to 12,030,218 common shares by Keystone Capital Partners, following a recent purchase agreement.

Aptose Biosciences is offering common shares and warrants, including pre-funded options, to raise capital for working capital and general corporate purposes.

Aptose Biosciences has filed a registration statement for a potential offering of common shares to raise capital for working capital and general corporate purposes.

Aptose Biosciences has filed a registration statement to register up to $3,360,871 in additional securities, including common shares, warrants, and underwriters' warrants.

Aptose Biosciences is launching a public offering of common shares and warrants, aiming to raise $9.9 million to support the development of its cancer treatment pipeline.

Hanmi Pharmaceutical Co., Ltd. has converted $1.51 million of debt into common shares of Aptose Biosciences Inc., increasing its beneficial ownership to 19.93% and securing enhanced investor rights, while Aptose plans a new $15 million capital raise.

Bleichroeder LP and affiliates report a passive 1.61% beneficial ownership in Aptose Biosciences Inc. common shares.

Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have jointly filed an amended Schedule 13G, reporting a passive beneficial ownership of 6.3% in Aptose Biosciences Inc.'s common shares.

Bleichroeder LP, along with Bleichroeder Holdings LLC and Andrew Gundlach, has filed an amended Schedule 13G disclosing a 7.5% beneficial ownership stake in Aptose Biosciences Inc.

Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach have disclosed a 6.2% beneficial ownership stake in Aptose Biosciences Inc. common shares through an amended Schedule 13G filing.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in Aptose Biosciences Inc.'s common shares as of December 31, 2024.

Bleichroeder LP and Bleichroeder Holdings LLC have disclosed a passive 6.2% beneficial ownership stake in Aptose Biosciences Inc. as of December 31, 2024.